Roche Advances AI-Derived Drug with Partner Recursion
August 6, 2026
Roche advanced the first project (aimed at treating an undisclosed neurodegenerative disease) from its AI drug-discovery partnership with Recursion – the first of as many as 40 potential programs under the collaboration, said Recursion Chief Executive Officer Najat Khan, PhD.
The Recursion option, which gives Roche the right to co-develop the newly identified target as a potential medicine, follows several years of work building what Recursion calls “maps of biology“ from more than one trillion lab-grown human neurons whose genes were systematically switched off one by one. The datasets can be mined repeatedly to generate additional drug targets.
“We’ve built a map,” said Christopher Winrow, Recursion’s vice president of neuroscience. Unlike traditional drug discovery, where “most of that data gets thrown away,” Recursion “can continue to go back to that map” to search for additional drug targets, he said.
*Requires Paid Subscription
Recent News
- Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA Initiation in Adults with IBS-C
- Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe
- Co-Diagnostics to Showcase Co-Dx PCR Platform* and MTB Test at WHX Labs Johannesburg, Highlight Ebola Assay Development
- Co-Diagnostics Highlights Vector Smart® Momentum Following New Federal Initiative on Vector-Borne Disease
- BlueWind Medical Announces Humana Coverage of Revi® for Urgency Urinary Incontinence, Expanding Access to Millions of Patients
- Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
